Kymera Therapeutics (KYMR) Misses Q4 EPS by 18c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.97), $0.18 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $15 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Trump: 40-60% of chip manufacturing will be in the U.S. - CNBC Interview
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold